Aligos Therapeutics, Inc.
- ALGS
- NASDAQ
- Biotechnology
- Viral/Liver Disease Drugs
- Antiviral Therapies
- Oligonucleotide Drugs
$4.84
Today −0.41%Quote Oct 19, 2026, 08:00 PM UTC
−6.00%over the last month
Max drawdown −14.4%From 1-month high −14.4%3 months −8.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
82
Market value
$50.5M
Approximate share count
Analyst target
$20.00
+313.2% from here
Floor
$4.80
0.9% below price
Resistance
$5.06
4.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALGSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free